Advances in melanoma senescence and potential clinical application

Pigment Cell and Melanoma Research

Volumn 24, Issue 2, 2011, Pages 295-308

  Giuliano, Sandy ^a,b   Ohanna, Mickaël ^a,b   Ballotti, Robert ^a,b,c   Bertolotto, Corine ^a,b,c  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Melanoma; Senescence

Indexed keywords

APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; ARF PROTEIN; B RAF KINASE; BETA CATENIN; BIOLOGICAL FACTOR; BRM PROTEIN; CANCER GROWTH FACTOR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; METALLOPROTEINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLTRANSFERASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN E7; PROTEIN KINASE SYK; PROTEIN P16; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN; SHORT HAIRPIN RNA; T BOX TRANSCRIPTION FACTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR E2F1; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CENTROSOME; CHROMOSOME 10; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; HELA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JUVENILE MELANOMA; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE H RAS; ONCOGENE N RAS; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYPLOIDY; REPLICATIVE SENESCENCE; REVIEW; SEQUENCE ANALYSIS; SIDE EFFECT; TELOMERE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

BIOLOGICAL MARKERS; CELL AGING; CELL CYCLE; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; ONCOGENE PROTEINS; ONCOGENES; PHENOTYPE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; T-BOX DOMAIN PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 79952599591     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00820.x     Document Type: Review

References (157)

1. Abdallah, P., Luciano, P., Runge, K.W., Lisby, M., Geli, V., Gilson, E., and Teixeira, M.T. (2009). A two-step model for senescence triggered by a single critically short telomere. Nat. Cell Biol. 11, 988-993.
2. Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., and Beermann, F. (2005). Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 4005-4011.
3. Acosta, J.C., O'Loghlen, A., Banito, A. et al. (2008). Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018.
4. d'Adda di Fagagna, F. (2008). Living on a break: cellular senescence as a DNA-damage response. Nat. Rev. Cancer 8, 512-522.
5. Adhikary, S., Marinoni, F., Hock, A. et al. (2005). The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 123, 409-421.
6. Alexiadis, V., Waldmann, T., Andersen, J., Mann, M., Knippers, R., and Gruss, C. (2000). The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev. 14, 1308-1312.
7. Angkeow, P., Deshpande, S.S., Qi, B., Liu, Y.X., Park, Y.C., Jeon, B.H., Ozaki, M., and Irani, K. (2002). Redox factor-1: an extra-nuclear role in the regulation of endothelial oxidative stress and apoptosis. Cell Death Differ. 9, 717-725.
8. Bailet, O., Fenouille, N., Abbe, P. et al. (2009). Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res. 69, 2748-2756.
9. Bandyopadhyay, D., and Medrano, E.E. (2000). Melanin accumulation accelerates melanocyte senescence by a mechanism involving p16INK4a/CDK4/pRB and E2F1. Ann. N Y Acad. Sci. 908, 71-84.
10. Bandyopadhyay, D., Okan, N.A., Bales, E., Nascimento, L., Cole, P.A., and Medrano, E.E. (2002). Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res. 62, 6231-6239.
11. Bandyopadhyay, D., Curry, J.L., Lin, Q., Richards, H.W., Chen, D., Hornsby, P.J., Timchenko, N.A., and Medrano, E.E. (2007). Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell 6, 577-591.
12. Bardeesy, N., Bastian, B.C., Hezel, A., Pinkel, D., DePinho, R.A., and Chin, L. (2001). Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol. Cell. Biol. 21, 2144-2153.
13. Bardeesy, N., Kim, M., Xu, J., Kim, R.S., Shen, Q., Bosenberg, M.W., Wong, W.H., and Chin, L. (2005). Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol. Cell. Biol. 25, 4176-4188.
14. Bartek, J., Lukas, J., and Bartkova, J. (2007). DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 6, 2344-2347.
15. Bastian, B.C. (2003). Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 22, 3081-3086.
16. Beausejour, C.M., Krtolica, A., Galimi, F., Narita, M., Lowe, S.W., Yaswen, P., and Campisi, J. (2003). Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212-4222.
17. Bennett, D.C. (2003). Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22, 3063-3069.
18. Bennett, D.C. (2008). How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21, 27-38.
19. Bennett, D.C., and Medrano, E.E. (2002). Molecular regulation of melanocyte senescence. Pigment Cell Res. 15, 242-250.
20. Ben-Porath, I., and Weinberg, R.A. (2005). The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 37, 961-976.
21. Bevona, C., Goggins, W., Quinn, T., Fullerton, J., and Tsao, H. (2003). Cutaneous melanomas associated with nevi. Arch. Dermatol. 139, 1620-1624; discussion 1624.
22. Biroccio, A., Amodei, S., Antonelli, A., Benassi, B., and Zupi, G. (2003). Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis. J. Biol. Chem. 278, 35693-35701.
23. Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A.H., Schlegelberger, B., Stein, H., Dorken, B., Jenuwein, T., and Schmitt, C.A. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665.
24. Brummelkamp, T.R., Kortlever, R.M., Lingbeek, M., Trettel, F., MacDonald, M.E., van Lohuizen, M., and Bernards, R. (2002). TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J. Biol. Chem. 277, 6567-6572.
25. Carreira, S., Liu, B., and Goding, C.R. (2000). The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J. Biol. Chem. 275, 21920-21927.
26. Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20, 3426-3439.
27. Carro, M.S., Spiga, F.M., Quarto, M., Di Ninni, V., Volorio, S., Alcalay, M., and Muller, H. (2006). DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 5, 1202-1207.
28. Cheli, Y., Ohanna, M., Ballotti, R., and Bertolotto, C. (2010). Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 23, 27-40.
29. Chen, Z., Trotman, L.C., Shaffer, D. et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730.
30. Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner 2nd, J.W., and DePinho, R.A. (1997). Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11, 2822-2834.
31. Collado, M., Gil, J., Efeyan, A. et al. (2005). Tumour biology: senescence in premalignant tumours. Nature 436, 642.
32. Coopman, P.J., Do, M.T., Barth, M. et al. (2000). The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406, 742-747.
33. Coppe, J.P., Desprez, P.Y., Krtolica, A., and Campisi, J. (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99-118.
34. Cozzi, S.J., Parsons, P.G., Ogbourne, S.M., Pedley, J., and Boyle, G.M. (2006). Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res. 66, 10083-10091.
35. Cronin, J.C., Wunderlich, J., Loftus, S.K. et al. (2009). Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res. 22, 435-444.
36. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky Jr, W.E., You, M.J., DePinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
37. Davis, E., Teng, H., Bilican, B., Parker, M.I., Liu, B., Carriera, S., Goding, C.R., and Prince, S. (2008). Ectopic Tbx2 expression results in polyploidy and cisplatin resistance. Oncogene 27, 976-984.
38. Delmas, V., Beermann, F., Martinozzi, S. et al. (2007). Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 21, 2923-2935.
39. Denoyelle, C., Abou-Rjaily, G., Bezrookove, V. et al. (2006). Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Biol. 8, 1053-1063.
40. Dhomen, N., Reis-Filho, J.S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., and Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294-303.
41. Di Micco, R., Fumagalli, M., Cicalese, A. et al. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638-642.
42. Felsher, D.W., and Bishop, J.M. (1999). Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl Acad. Sci. U S A 96, 3940-3944.
43. Freedberg, D.E., Rigas, S.H., Russak, J. et al. (2008). Frequent p16-independent inactivation of p14ARF in human melanoma. J. Natl Cancer Inst. 100, 784-795.
44. Freund, A., Orjalo, A.V., Desprez, P.Y., and Campisi, J. (2010). Inflammatory networks during cellular senescence: causes and consequences. Trends Mol. Med. 16, 238-246.
45. Gamble, M.J., and Fisher, R.P. (2007). SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat. Struct. Mol. Biol. 14, 548-555.
46. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
47. Gartel, A.L., and Shchors, K. (2003). Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp. Cell Res. 283, 17-21.
48. Giuliano, S., Cheli, Y., Ohanna, M. et al. (2010). Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res. 70, 3813-3822.
49. Goel, V.K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F.S., Hinds, P.W., and Haluska, F.G. (2009). Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28, 2289-2298.
50. Goldstein, A.M., Chan, M., Harland, M. et al. (2006). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 66, 9818-9828.
51. Goodall, J., Wellbrock, C., Dexter, T.J., Roberts, K., Marais, R., and Goding, C.R. (2004). The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell. Biol. 24, 2923-2931.
52. Goodall, J., Carreira, S., Denat, L., Kobi, D., Davidson, I., Nuciforo, P., Sturm, R.A., Larue, L., and Goding, C.R. (2008). Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res. 68, 7788-7794.
53. Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D., and Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505.
54. Gruber, S.B., Barnhill, R.L., Stenn, K.S., and Roush, G.C. (1989). Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J. Am. Acad. Dermatol. 21, 773-780.
55. Guney, I., Wu, S., and Sedivy, J.M. (2006). Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc. Natl Acad. Sci. U S A 103, 3645-3650.
56. Ha, L., Ichikawa, T., Anver, M. et al. (2007). ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl Acad. Sci. U S A 104, 10968-10973.
57. Ha, L., Merlino, G., and Sviderskaya, E.V. (2008). Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle 7, 1944-1948.
58. Haferkamp, S., Becker, T.M., Scurr, L.L., Kefford, R.F., and Rizos, H. (2008). p16INK4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell 7, 733-745.
59. Hayflick, L., and Moorhead, P.S. (1961). The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585-621.
60. Heo, J.Y., Jing, K., Song, K.S. et al. (2009). Downregulation of APE1/Ref-1 is involved in the senescence of mesenchymal stem cells. Stem Cells 27, 1455-1462.
61. Hirose, Y., Berger, M.S., and Pieper, R.O. (2001). p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61, 1957-1963.
62. Ho, J.S., Ma, W., Mao, D.Y., and Benchimol, S. (2005). p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell. Biol. 25, 7423-7431.
63. Hoek, K., Rimm, D.L., Williams, K.R. et al. (2004). Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64, 5270-5282.
64. Hoeller, C., Thallinger, C., Pratscher, B., Bister, M.D., Schicher, N., Loewe, R., Heere-Ress, E., Roka, F., Sexl, V., and Pehamberger, H. (2005). The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J. Invest. Dermatol. 124, 1293-1299.
65. + exon 2a are functionally similar. Pigment Cell Melanoma Res. 21, 379-387.
66. Hussein, M.R., Haemel, A.K., and Wood, G.S. (2003). p53-related pathways and the molecular pathogenesis of melanoma. Eur. J. Cancer Prev. 12, 93-100.
67. Inamdar, G.S., Madhunapantula, S.V., and Robertson, G.P. (2010). Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem. Pharmacol. 80, 624-637.
68. Ismail, A., and Bateman, A. (2009). Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma. Cancer Lett. 278, 230-240.
69. Jacobs, J.J., Keblusek, P., Robanus-Maandag, E. et al. (2000). Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 26, 291-299.
70. Jane-Valbuena, J., Widlund, H.R., Perner, S. et al. (2010). An oncogenic role for ETV1 in melanoma. Cancer Res. 70, 2075-2084.
71. Jones, R., Ruas, M., Gregory, F., Moulin, S., Delia, D., Manoukian, S., Rowe, J., Brookes, S., and Peters, G. (2007). A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6. Cancer Res. 67, 9134-9141.
72. Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R., Ashmun, R.A., Grosveld, G., and Sherr, C.J. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659.
73. Kannengiesser, C., Brookes, S., del Arroyo, A.G. et al. (2009). Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. Hum. Mutat. 30, 564-574.
74. Kappes, F., Fahrer, J., Khodadoust, M.S., Tabbert, A., Strasser, C., Mor-Vaknin, N., Moreno-Villanueva, M., Burkle, A., Markovitz, D.M., and Ferrando-May, E. (2008). DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol. Cell. Biol. 28, 3245-3257.
75. Khodadoust, M.S., Verhaegen, M., Kappes, F., Riveiro-Falkenbach, E., Cigudosa, J.C., Kim, D.S., Chinnaiyan, A.M., Markovitz, D.M., and Soengas, M.S. (2009). Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 69, 6405-6413.
76. King, R., Googe, P.B., Weilbaecher, K.N., Mihm Jr, M.C., and Fisher, D.E. (2001). Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am. J. Surg. Pathol. 25, 51-57.
77. Krizhanovsky, V., Yon, M., Dickins, R.A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., and Lowe, S.W. (2008). Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657-667.
78. Kuilman, T., Michaloglou, C., Vredeveld, L.C., Douma, S., van Doorn, R., Desmet, C.J., Aarden, L.A., Mooi, W.J., and Peeper, D.S. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031.
79. Kurz, D.J., Decary, S., Hong, Y., and Erusalimsky, J.D. (2000). Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell Sci. 113(Pt 20), 3613-3622.
80. Lazzerini Denchi, E., Attwool, C., Pasini, D., and Helin, K. (2005). Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol. Biol. Cell 25, 2660-2672.
81. Lee, B.Y., Han, J.A., Im, J.S., Morrone, A., Johung, K., Goodwin, E.C., Kleijer, W.J., DiMaio, D., and Hwang, E.S. (2006). Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5, 187-195.
82. Leikam, C., Hufnagel, A., Schartl, M., and Meierjohann, S. (2008). Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence. Oncogene 27, 7070-7082.
83. Lewis, D.A., Yi, Q., Travers, J.B., and Spandau, D.F. (2008). UVB-induced senescence in human keratinocytes requires a functional insulin-like growth factor-1 receptor and p53. Mol. Biol. Cell 19, 1346-1353.
84. Liang, J., and Slingerland, J.M. (2003). Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2, 339-345.
85. von Lindern, M., van Baal, S., Wiegant, J., Raap, A., Hagemeijer, A., and Grosveld, G. (1992). Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol. Cell. Biol. 12, 3346-3355.
86. Liu, F., Fu, Y., and Meyskens Jr, F.L. (2009). MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J. Invest. Dermatol. 129, 422-431.
87. Lodygin, D., Menssen, A., and Hermeking, H. (2002). Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J. Clin. Invest. 110, 1717-1727.
88. Mahabeleshwar, G.H., and Kundu, G.C. (2003). Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells. J. Biol. Chem. 278, 6209-6221.
89. Mallette, F.A., Gaumont-Leclerc, M.F., and Ferbeyre, G. (2007). The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 21, 43-48.
90. Mhaidat, N.M., Zhang, X.D., Allen, J., Avery-Kiejda, K.A., Scott, R.J., and Hersey, P. (2007). Temozolomide induces senescence but not apoptosis in human melanoma cells. Br. J. Cancer 97, 1225-1233.
91. Michaloglou, C., Vredeveld, L.C., Soengas, M.S., Denoyelle, C., Kuilman, T., van der Horst, C.M., Majoor, D.M., Shay, J.W., Mooi, W.J., and Peeper, D.S. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
92. Michaloglou, C., Vredeveld, L.C., Mooi, W.J., and Peeper, D.S. (2008). BRAF(E600) in benign and malignant human tumours. Oncogene 27, 877-895.
93. Mishra, P.J., Ha, L., Rieker, J., Sviderskaya, E.V., Bennett, D.C., Oberst, M.D., Kelly, K., and Merlino, G. (2010). Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene 29, 2449-2456.
94. Mocsai, A., Ruland, J., and Tybulewicz, V.L. (2010). The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387-402.
95. Muthusamy, V., Duraisamy, S., Bradbury, C.M., Hobbs, C., Curley, D.P., Nelson, B., and Bosenberg, M. (2006). Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 66, 11187-11193.
96. Narita, M., Krizhanovsky, V., Nunez, S., Chicas, A., Hearn, S.A., Myers, M.P., and Lowe, S.W. (2006). A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126, 503-514.
97. Naumann, S.C., Roos, W.P., Jost, E., Belohlavek, C., Lennerz, V., Schmidt, C.W., Christmann, M., and Kaina, B. (2009). Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br. J. Cancer 100, 322-333.
98. Nazarian, R.M., Prieto, V.G., Elder, D.E., and Duncan, L.M. (2010). Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J. Cutan. Pathol. 37(Suppl. 1), 41-47.
99. Nogueira, C., Kim, K.H., Sung, H., Paraiso, K.H., Dannenberg, J.H., Bosenberg, M., Chin, L., and Kim, M. (2010). Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 29, 6222-6232.
100. Olumi, A.F., Grossfeld, G.D., Hayward, S.W., Carroll, P.R., Tlsty, T.D., and Cunha, G.R. (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011.
101. Papaioannou, V.E. (2001). T-box genes in development: from hydra to humans. Int. Rev. Cytol. 207, 1-70.
102. Passos, J.F., Nelson, G., Wang, C. et al. (2010). Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol. Syst. Biol. 6, 347.
103. Patton, E.E., Widlund, H.R., Kutok, J.L. et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254.
104. Pelengaris, S., Khan, M., and Evan, G. (2002). c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2, 764-776.
105. Petti, C., Molla, A., Vegetti, C., Ferrone, S., Anichini, A., and Sensi, M. (2006). Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res. 66, 6503-6511.
106. te Poele, R.H., Okorokov, A.L., Jardine, L., Cummings, J., and Joel, S.P. (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62, 1876-1883.
107. Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J. et al. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723.
108. Poynter, J.N., Elder, J.T., Fullen, D.R., Nair, R.P., Soengas, M.S., Johnson, T.M., Redman, B., Thomas, N.E., and Gruber, S.B. (2006). BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 16, 267-273.
109. Prince, S., Carreira, S., Vance, K.W., Abrahams, A., and Goding, C.R. (2004). Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res. 64, 1669-1674.
110. Rajaraman, R., Guernsey, D.L., Rajaraman, M.M., and Rajaraman, S.R. (2006). Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int. 6, 25.
111. Rastogi, S., Joshi, B., Dasgupta, P., Morris, M., Wright, K., and Chellappan, S. (2006). Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol. Cell. Biol. 26, 4161-4171.
112. Riveiro-Falkenbach, E., and Soengas, M.S. (2010). Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin. Cancer Res. 16, 2932-2938.
113. Ryu, S.J., Cho, K.A., Oh, Y.S., and Park, S.C. (2006). Role of Src-specific phosphorylation site on focal adhesion kinase for senescence-associated apoptosis resistance. Apoptosis 11, 303-313.
114. Ryu, S.J., Oh, Y.S., and Park, S.C. (2007). Failure of stress-induced downregulation of Bcl-2 contributes to apoptosis resistance in senescent human diploid fibroblasts. Cell Death Differ. 14, 1020-1028.
115. Sage, J., Mulligan, G.J., Attardi, L.D., Miller, A., Chen, S., Williams, B., Theodorou, E., and Jacks, T. (2000). Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 14, 3037-3050.
116. Sarkisian, C.J., Keister, B.A., Stairs, D.B., Boxer, R.B., Moody, S.E., and Chodosh, L.A. (2007). Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9, 493-505.
117. Sauter, E.R., Yeo, U.C., von Stemm, A. et al. (2002). Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 62, 3200-3206.
118. Schmitt, C.A., Fridman, J.S., Yang, M., Lee, S., Baranov, E., Hoffman, R.M., and Lowe, S.W. (2002). A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346.
119. Schwahn, D.J., Timchenko, N.A., Shibahara, S., and Medrano, E.E. (2005). Dynamic regulation of the human dopachrome tautomerase promoter by MITF, ER-alpha and chromatin remodelers during proliferation and senescence of human melanocytes. Pigment Cell Res. 18, 203-213.
120. Sharpless, N.E., Ramsey, M.R., Balasubramanian, P., Castrillon, D.H., and DePinho, R.A. (2004). The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 23, 379-385.
121. Smalley, K.S., Lioni, M., Dalla Palma, M. et al. (2008). Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 7, 2876-2883.
122. Soares, L.M., Zanier, K., Mackereth, C., Sattler, M., and Valcarcel, J. (2006). Intron removal requires proofreading of U2AF/3' splice site recognition by DEK. Science 312, 1961-1965.
123. Soengas, M.S., and Lowe, S.W. (2003). Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3151.
124. Soengas, M.S., Capodieci, P., Polsky, D. et al. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211.
125. Sotillo, R., Dubus, P., Martin, J., de la Cueva, E., Ortega, S., Malumbres, M., and Barbacid, M. (2001). Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20, 6637-6647.
126. Soufir, N., Avril, M.F., Chompret, A., Demenais, F., Bombled, J., Spatz, A., Stoppa-Lyonnet, D., Benard, J., and Bressac-de Paillerets, B. (1998). Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum. Mol. Genet. 7, 209-216.
127. Steinert, S., Shay, J.W., and Wright, W.E. (2000). Transient expression of human telomerase extends the life span of normal human fibroblasts. Biochem. Biophys. Res. Commun. 273, 1095-1098.
128. Strub, T., Giuliano, S., Ye, T. et al. (in press). Essential role of Microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene.
129. Sviderskaya, E.V., Hill, S.P., Evans-Whipp, T.J., Chin, L., Orlow, S.J., Easty, D.J., Cheong, S.C., Beach, D., DePinho, R.A., and Bennett, D.C. (2002). p16(Ink4a) in melanocyte senescence and differentiation. J. Natl Cancer Inst. 94, 446-454.
130. Sviderskaya, E.V., Gray-Schopfer, V.C., Hill, S.P. et al. (2003). p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J. Natl Cancer Inst. 95, 723-732.
131. Tada, M., and Smith, J.C. (2001). T-targets: clues to understanding the functions of T-box proteins. Dev. Growth Differ. 43, 1-11.
132. Terzian, T., Torchia, E.C., Dai, D. et al. (2010). p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res23, 781-794.
133. Vance, K.W., Carreira, S., Brosch, G., and Goding, C.R. (2005). Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 65, 2260-2268.
134. Veal, E.A., Day, A.M., and Morgan, B.A. (2007). Hydrogen peroxide sensing and signaling. Mol. Cell 26, 1-14.
135. Waldmann, T., Scholten, I., Kappes, F., Hu, H.G., and Knippers, R. (2004). The DEK protein - an abundant and ubiquitous constituent of mammalian chromatin. Gene 343, 1-9.
136. Wang, S., Ding, Y.B., Chen, G.Y., Xia, J.G., and Wu, Z.Y. (2004). Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma. World J. Gastroenterol. 10, 1815-1818.
137. Wang, H., Mannava, S., Grachtchouk, V., Zhuang, D., Soengas, M.S., Gudkov, A.V., Prochownik, E.V., and Nikiforov, M.A. (2008). c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27, 1905-1915.
138. Wellbrock, C., and Schartl, M. (1999). Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc. Eur. J. Biochem. 260, 275-283.
139. Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., and Marais, R. (2008). Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3, e2734.
140. Willis-Martinez, D., Richards, H.W., Timchenko, N.A., and Medrano, E.E. (2010). Role of HDAC1 in senescence, aging, and cancer. Exp. Gerontol. 45, 279-285.
141. Wise-Draper, T.M., Allen, H.V., Thobe, M.N., Jones, E.E., Habash, K.B., Munger, K., and Wells, S.I. (2005). The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J. Virol. 79, 14309-14317.
142. Wise-Draper, T.M., Allen, H.V., Jones, E.E., Habash, K.B., Matsuo, H., and Wells, S.I. (2006). Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol. Cell. Biol. 26, 7506-7519.
143. Witt, O., Deubzer, H.E., Milde, T., and Oehme, I. (2009). HDAC family: What are the cancer relevant targets? Cancer Lett. 277, 8-21.
144. Wu, C.H., van Riggelen, J., Yetil, A., Fan, A.C., Bachireddy, P., and Felsher, D.W. (2007). Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl Acad. Sci. U S A 104, 13028-13033.
145. Wu, Q., Li, Z., Lin, H., Han, L., Liu, S., and Lin, Z. (2008). DEK overexpression in uterine cervical cancers. Pathol. Int. 58, 378-382.
146. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., and Lowe, S.W. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
147. Yarosh, W., Barrientos, T., Esmailpour, T., Lin, L., Carpenter, P.M., Osann, K., Anton-Culver, H., and Huang, T. (2008). TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res. 68, 693-699.
148. Yeo, E.J., Hwang, Y.C., Kang, C.M., Choy, H.E., and Park, S.C. (2000). Reduction of UV-induced cell death in the human senescent fibroblasts. Mol. Cells 10, 415-422.
149. You, M.J., Castrillon, D.H., Bastian, B.C., O'Hagan, R.C., Bosenberg, M.W., Parsons, R., Chin, L., and DePinho, R.A. (2002). Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl Acad. Sci. U S A 99, 1455-1460.
150. Zaky, A., Busso, C., Izumi, T., Chattopadhyay, R., Bassiouny, A., Mitra, S., and Bhakat, K.K. (2008). Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage. Nucleic Acids Res. 36, 1555-1566.
151. Zhang, S., and Yu, D. (2010). PI(3)king apart PTEN's role in cancer. Clin. Cancer Res. 16, 4325-4330.
152. Zhang, Y., Xiong, Y., and Yarbrough, W.G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.
153. Zhu, J., Blenis, J., and Yuan, J. (2008). Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc. Natl Acad. Sci. U S A 105, 6584-6589.
154. Zhu, S., Wurdak, H., Wang, Y. et al. (2009). A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc. Natl Acad. Sci. U S A 106, 17025-17030.
155. Zhuang, D., Mannava, S., Grachtchouk, V. et al. (2008). c-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 27, 6623-6634.
156. Zuo, L., Weger, J., Yang, Q., Goldstein, A.M., Tucker, M.A., Walker, G.J., Hayward, N., and Dracopoli, N.C. (1996). Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12, 97-99.
157. Zyss, D., Montcourrier, P., Vidal, B., Anguille, C., Merezegue, F., Sahuquet, A., Mangeat, P.H., and Coopman, P.J. (2005). The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression. Cancer Res. 65, 10872-10880.